Overview

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Status:
Completed
Trial end date:
2015-02-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.
Phase:
Phase 2
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborator:
Cascadian Therapeutics Inc.